Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors
Open accessThe DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
Abstract Small molecular PD‐1 inhibitors are lacking in current immuno‐oncology clinic. PD‐1/PD‐L1 antibody inhibitors currently approved for clinical usage block interaction between PD‐L1 and PD‐1 to enhance cytotoxicity of CD8 + cytotoxic T lymphocyte (CTL). Whether other steps along the PD‐1 signaling pathway can be targeted remains to be determined. Here, we report that methylene blue (MB), an FDA‐approved chemical for treating methemoglobinemia, potently inhibits PD‐1 signaling. MB enhances the cytotoxicity, activation, cell proliferation, and cytokine‐secreting activity of CTL inhibited by PD‐1. Mechanistically, MB blocks interaction between Y248‐phosphorylated immunoreceptor tyrosine‐based switch motif (ITSM) of human PD‐1 and SHP2. MB enables activated CTL to shrink PD‐L1 expressing tumor allografts and autochthonous lung cancers in a transgenic mouse model. MB also effectively counteracts the PD‐1 signaling on human T cells isolated from peripheral blood of healthy donors. Thus, we identify an FDA‐approved chemical capable of potently inhibiting the function of PD‐1. Equally important, our work sheds light on a novel strategy to develop inhibitors targeting PD‐1 signaling axis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Even though SHP2 is important for inhibitory signaling of PD‐1 in most cases, T lymphocyte SHP2 deficiency can still be detrimental by reacting to the treatment of anti‐PD‐1 antibodies in vitro, thus revealing an alternate signaling pathway [284, 285].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [284]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, interfering with the interaction of SHP2 with programmed death-1 (PD-1) is a potent alternative to immuno-oncologic approaches aiming to block PD-1 with antibodies in several cancers [53].”
From The tyrosine phosphatase SHP2 increases robustness and information transfer within IL-6-induced JAK/STAT signalling (2021) · cites this paper as [53]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“Impressive clinical benefit was seen in a portion of cancer patients (Brahmer et al, 2010; Topalian et al, 2012; Powles et al, 2014).”
BackgroundSelf-citationBrahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961 · cited 2×
“Impressive clinical benefit was seen in a portion of cancer patients (Brahmer et al, 2010; Topalian et al, 2012; Powles et al, 2014).”
BackgroundSelf-citationNishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · cited 1×
“In contrast, PD-1-deficient mice of C57BL/6 background develop and grow apparently normally, with autoimmune disease observed in late stage of their life (Nishimura et al, 1998, 1999).”
BackgroundMPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Bellmunt, J., Burris, H. A., Petrylak, D. P., Teng, S.-L., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,381 · cited 1×
“Impressive clinical benefit was seen in a portion of cancer patients (Brahmer et al, 2010; Topalian et al, 2012; Powles et al, 2014).”
BackgroundFulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308 · cited 1×
“Unfortunately, PD-1 inhibitors currently used in clinic show severe, sometimes fatal, side effects (Johnson et al, 2016; Moslehi et al, 2018).”
BackgroundT cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689
Self-citationDecker, T., & Lohmann-Matthes, M.-L. (1988) · Journal of Immunological Methods · doi:10.1016/0022-1759(88)90310-9 · Cited by 1,359 · cited 1×
“Measuring lactate dehydrogenase (LDH) released by target tumor cells into medium is another accurate assay to determine CTL cytotoxicity (Decker & Lohmann-Matthes, 1988).”
MethodYokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161 · cited 17×
“Although SHP1 and SHP2 were earlier reported to be recruited by PD-1 to exert immunoinhibitory function, it is been confirmed that SHP2 is the main effecter (Yokosuka et al, 2012).”
BackgroundInfluential
Cited by
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
Wei, J., Li, W., Zhang, P., Guo, F., & Liu, M. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02179-5 · Cited by 160
Immune checkpoint inhibitors: breakthroughs in cancer treatment
Kong, X., Zhang, J., Chen, S., Wang, X., Xi, Q., Shen, H., & Zhang, R. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2024.0055 · Cited by 203
“The core of PD-1’s inhibitory function lies in the ITSM-Y248 residue rather than the ITIM-Y223 residue 12 .”
BackgroundPan, J., Zhou, L., Zhang, C., Xu, Q., & Sun, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01038-3 · Cited by 129
“found that methylene blue prevented SHP2 from binding with Y248-phosphorylated PD-1 and therefore enhanced the tumorkilling effect of CTLs.(264) In addition, inducing the degradation and ubiquitination of SHP2 through its intracellular E3 ligase, FBXW7, was an outstanding approach that interrupted the downstream signa…”
BackgroundA comprehensive review of SHP2 and its role in cancer
Asmamaw, M. D., Shi, X.-J., Zhang, L.-R., & Liu, H.-M. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00698-1 · Cited by 119
Metadata
- Authors
- Fan, Z., Tian, Y., Chen, Z., Liu, L., Zhou, Q., He, J., Coleman, J., Dong, C., Li, N., Huang, J., Xu, C., Zhang, Z., Gao, S., Zhou, P., Ding, K., & Chen, L.
- Affiliations
- Jinan University (CN)
- Sun Yat-sen University Cancer Center (CN)
- University of East Anglia (GB)
- Chinese Academy of Sciences (CN)
- Corresponding author
- Zhou, Penghui
- Ding, Ke
- Chen, Liang
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2020-05-11
- Volume
- 12
- Issue
- 6
- Pages
- e11571-e11571
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC7278553
- OpenAlex
- W3023016632
- Cited by
- 62
- References
- 51
- Citations by year
- 2026: 7 · 2025: 6 · 2024: 16 · 2023: 7 · 2022: 17 · 2021: 6 · 2020: 3
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UEA Digital Repository (University of East Anglia) (acceptedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- NSF|Foundation for Innovative Research Groups of the National Natural Science Foundation of China (81672309, 81972778, 31800723, 31701174)
- Guangzhou Research Project of Science and Technology for Citizen Health (201803010124)
- Science and Technology Program of Guangdong (2017B020227001)
- Fundamental Research Funds for the Central Universities (21618326)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- PD-1, SHP2, methylene blue, PD-1/PD-L1 axis, CD8+ cytotoxic T lymphocytes, lung cancer, immunotherapy, tumor allografts
- MeSH terms
- Immune Checkpoint Inhibitors, Animals, Antineoplastic Agents, Humans, T-Lymphocytes, Cytotoxic, CD8-Positive T-Lymphocytes, Mice, Protein Tyrosine Phosphatase, Non-Receptor Type 11, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors. https://app.cochat.ai/papers/10.15252/emmm.201911571
- The paper
- Fan, Z., Tian, Y., Chen, Z., Liu, L., Zhou, Q., He, J., Coleman, J., Dong, C., Li, N., Huang, J., Xu, C., Zhang, Z., Gao, S., Zhou, P., Ding, K., & Chen, L. (2020). Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201911571
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.